Scientific and Medical Advisory Board (SMAB)

//Scientific and Medical Advisory Board (SMAB)
Scientific and Medical Advisory Board (SMAB) 2019-11-18T01:02:09+00:00

Scientific and Medical Advisory Board (SMAB)

The Scientific & Medical Advisory Board (SMAB) is established to provide the Board of Directors of the Carcinoid NeuroEndocrine Tumour Society of Canada (CNETS Canada) with independent, expert, multi-disciplinary, and strategic advice on the status of current and upcoming medical and scientific issues related to diagnosis, therapy and better management of treatment of NET patients. The SMAB will also assess and recommend potential medical and scientific partnerships and linkages that can advance the mandate of CNETS Canada. The CNETS Canada Board of Directors (the Board) will carefully assess all the recommendations of the SMAB but will retain the final authority and responsibilities for taking any decision pursuant to those recommendations.

2019 Scientific and Medical Advisory Board Members

Dr. Jean-Luc Urbain
Dr. Jean-Luc UrbainCo-Chair
Dr. Shereen Ezzat
Dr. Shereen EzzatCo-Chair
Dr. Sylvia Asa
Dr. Sylvia Asa
Dr. Jean-Mathieu Beauregard
Dr. Jean-Mathieu Beauregard
Dr. Denise Chan
Dr. Denise Chan
Dr. Rachel Goodwin
Dr. Rachel Goodwin
Dr. Julie Hallet
Dr. Julie Hallet
Dr. Cynthia Landry
Dr. Cynthia Landry
Dr. Ozgur Mete
Dr. Ozgur Mete
Dr. Janice Pasieka
Dr. Janice Pasieka
Dr. Dean Ruether
Dr. Dean Ruether
Dr. Girish Shah
Dr. Girish Shah

SMAB Member Bios

Co-Chair Dr. Jean-Luc Urbain MD, PhD, CPE (Nuclear Medicine)

Dr. Urbain has been an active member of the Medical Community for more than 25 years. After earning his Medical Degree, Urbain pursued residency training in Internal Medicine and Medical Imaging. He obtained a Ph.D. in Genetics and Molecular Biology at Temple University, In Philadelphia. Urbain has been Professor of Medicine and Diagnostic Imaging for more than two decades. He has hold leadership positions at Fox Chase Cancer Center, the Cleveland Clinic, the University of Western Ontario and more recently in the Veteran Health Administration. As a teacher and leader Urbain has made significant contribution to the field of Molecular Imaging. Urbain has extensive experience and expertise in committees and boards leadership and management in integrated health care systems and patient advocacy groups and at regional, national and international levels of government. Urbain has been privileged to work closely with medical associations and government health authorities to mitigate major health crisis, analyzed and helped establish medical resources needs, benchmarks and allocation for key medical service areas. He has served as a consultant and advisor for Pharmaceutical and Medical Systems companies such as Janssen & Janssen, Glaxo, Smith Kline Beecham, GE and Siemens. He has also worked in the medical industry as senior director, advisor and investigator for the clinical validation of new technology/ products.
Urbain current main interests are in Physicians Performance Improvement, Patient Education and Advocacy and Personalized Medicine.

Co-Chair Dr. Shereen Ezzat MD, FRCP(C), FACP (Endocrine Oncology)

Shereen Ezzat, M.D., FRCP(C), FACP, Professor of Medicine & Oncology, Endocrine Oncology Site Group, Princess Margaret Cancer Centre, University Health Network. Dr. Ezzat obtained his medical degree from the University of Manitoba, completed his residency training at the University of British Columbia, and his post-doctoral research training in molecular oncology at Cedars-Sinai-UCLA School of Medicine in Los Angeles. Dr. Ezzat has authored or co-authored more than 250 original research articles and 40 invited review articles, and he has delivered more than 150 invited lectures. He supervises undergraduate and graduate students, as well as postdoctoral fellows. He teaches a number of courses, including physiology, biochemistry, and developmental biology. Dr. Ezzat served as an Editorial Board member for a number of journals including Endocrinology, Journal of Clinical Endocrinology & Metabolism, American Journal of Physiology, Journal of Endocrinology, Endocrine Practice, and BMJ-Endocrine. He is a regular reviewer for the New England Journal of Medicine and the Annals of Internal Medicine.

Dr. Sylvia Asa MD, PhD (Pathology)

Sylvia L. Asa, MD, PhD, Endocrine Pathologist, Professor, Department of Laboratory Medicine and Pathobiology, University of Toronto, has published over 400 scientific articles, written five books, co-edited five books and contributed 100 book chapters on endocrine pathology. She serves on numerous editorial boards of scientific journals and has given over 200 invited lectures. Dr. Asa was President of the Endocrine Pathology Society (1997–1998) and the US-Canadian Academy of Pathology (2005-6) and has received many awards from national and international scientific organizations.
As head of the largest pathology department in Canada for 15 years, Dr. Asa made innovative changes to the practice of the discipline, with emphasis on subspecialization, automation, electronic initiatives and telepathology. She has emphasized the importance of education and research. To ensure public knowledge of the role of Pathology and maintain a direct connection with patients, Dr. Asa is a consultant to several patient groups.

Dr. Jean-Mathieu Beauregard MD, MSc, FRCPC (Nuclear Medicine)

Assistant Professor, Université Laval – Nuclear Medicine Physician, CHU de Québec-Université Laval – Clinician-Scientist, CRCHU de Québec-Université Laval
Dr. Jean-Mathieu Beauregard is Assistant Professor in the Department of Radiology and Nuclear Medicine at Université Laval and Clinician-Scientist at CHU de Québec in Quebec City, Canada. He has over 12 years of experience in dosimetry based on quantitative imaging, including PET and SPECT. During his fellowship at the Peter MacCallum Cancer Centre, he developed his expertise in molecular imaging and radionuclide therapy of neuroendocrine tumours, one of the most successful theranostic application in nuclear medicine to date. Upon his return to CHU de Québec, he started a PRRT program and, more recently, launched a first-of-its-kind prospective clinical trial of personalized Lu-177-octreotate PRRT. Through this trial, quantitative SPECT-based dosimetry methods will be optimized in collaboration with a team of physicists. Dr. Beauregard also conducts a pre-clinical research program in which he investigates the application of novel radiosensitizing approaches for radionuclide therapy. Besides, he is also involved in molecular imaging research in the fields of prostate cancer and dementia.

Dr. Denise Chan MD, FRCPC (Nuclear Medicine)

Dr. Rachel Goodwin MD, FRCPC (Medical Oncology)

Dr. Rachel Goodwin completed her medical oncology training at the University of Ottawa.  She went on to complete a two year Investigational New Drug Development Fellowship at the Canadian Cancer Trials Group, Queens University.  She is an Assistant Professor in the Faculty of Medicine at the University of Ottawa.  Her clinical interests include gastrointestinal cancers, neuroendocrine cancers and new drug development.  

Dr. Goodwin has been actively involved in the development of national NET consensus guidelines and presenting neuroendocrine topics for Oncology Education and CNETS (Carcinoid-Neuroendocrine Tumour Society of Canada).   As well, she was appointed to the CommNETS (Commonwealth Neuroendocrine Tumour Group) Planning and Project Oversight Committee.  She is also an expert member on the Cancer Care Ontario (CCO) PRRT Regional Access Committee and Neuroendocrine Tumour Advisory Committee.

Dr. Julie Hallet MD, MSc, FRCSC (Surgery)

Dr. Cynthia Landry MD (Primary Care Medicine)

After earning her Medical Degree from Université de Sherbrooke, Dr Landry completed her residency training in Primary Care Medicine at Université de Montréal. She is working as an emergency physician in Anna-Laberge Hospital (Châteauguay) since 2012.  As a McGill University Clinical Faculty Lecturer, she supervises and evaluate undergraduate and graduate students in their emergency medicine rotation. She is also a tutor for the Endocrinology & Reproduction phase at University de Montréal. Dr. Landry aims to improve awareness of NET among general practitioners and ER doctors.

Dr. Ozgur Mete MD, FRCPC (Pathology)

Ozgur Mete, MD, FRCPC is a Consultant Endocrine Pathologist at the University Health Network and Associate Professor in the Department of Laboratory Medicine and Pathobiology at the University of Toronto. Dr. Mete received his medical degree from Istanbul University in 2001 and completed his residency training in Anatomical Pathology at Istanbul University in 2005. He then did fellowship training in endocrine pathology under the supervision of Professor Sylvia Asa at the University of Toronto. He was appointed as an academic pathologist at Istanbul University before joining the faculty at the University of Toronto in 2011.

Dr. Janice Pasieka MD, FRCSC, FACS (Surgery)

Dr. Janice L Pasieka graduated from the University of Western Medical School and did her General Surgery Training at the University of Calgary. She then did two and a half years of Endocrine Surgical Training. The first year was spent in Dr. David Hanley’s lab at the University of Calgary, then a year at the University of Michigan, under the mentorship of Dr. Norman Thompson followed by time at the Karolinska Institute in Stockholm, Sweden. She then returned to Calgary and has devoted her clinical practice solely to endocrine surgical diseases. At the Tom Baker Clinic Center, Dr. Pasieka was the driving force behind the development of a multidisciplinary clinic for Neuroendocrine Tumors as well as the Multidisciplinary Hereditary Endocrine Clinic. She is responsible for the development of the only Canadian AAES accredited fellowship program in Endocrine Surgery. Dr. Pasieka has been Secretary-Treasurer of the American Association of Endocrine Surgeons (AAES) and in 2010 she became the first Canadian and second woman to become President. She has served on the Council of the International Association of Endocrine Surgeons (IAES), and in 2016 became the Secretary-Treasurer, a position she holds at the present time. Dr. Pasieka was the Canadian James IV Traveling Surgical Fellow 2006 and recently was appointed to the James IV Board of Directors. In 2007, the Women’s Executive Network named her as one of Canada’s 100 Most Powerful Women. Dr Pasieka recently completed her 6 year term as a Governor of the American College of Surgeons. Her areas of interests (besides running, mountain biking, cycling and hiking & snowshoeing with her dog Kocher) evolve around neuroendocrine tumors, adrenal disease, thyroid cancer and the study of surgical outcomes in patients with hyperparathyroidism. To date she has over 140 peer-review publications, has edited 3 Endocrine Surgical textbooks and written over 24 book chapters.

Dr. Dean Ruether MD, FRCSC (Medical Oncology)

Dr. Dean Ruether is Medical Director, Community Oncology, CancerControl Alberta as well as a Medical Oncologist at the Tom Baker Cancer Centre, Calgary, working in the GU, Endocrine and Breast programs for over 20 years. His undergraduate training was done at the University of Calgary and medical school completed at the University of Alberta.  Post graduate training in internal medicine, hematology and medical oncology was completed at the University of Calgary with focus on Clinical Trials in GU, Endocrine and Neuroendocrine malignancies, and Patient Education. Dr. Ruether also continues his position as Assistant Professor for Departments of Oncology and Medicine, Cumming School of Medicine, University of Calgary. Clinical oncology practice has always been Dr Ruether’s greatest passion.  He continues to enjoy his involvement in clinical trials within the Hematology, Breast, GU and Endocrine programs. Teaching medical trainees, including his role as the supervisor of the medical oncology residents’ longitudinal clinic from 2000 to 2009, and the awards he has received for teaching have been very gratifying.  His greatest challenge currently is his Medical Director role for the Community Oncology program including the 4 regional centers in Lethbridge, Medicine Hat, Red Deer and Grande Prairie and the 11 infusion community clinics across the province.  It is a pleasure to see some of the hard work over the last 21 months coming to fruition and creating more opportunities for Alberta patients and their families affected by cancer to receive more of their care closer to home.

Dr. Girish Shah PhD (Research)

PROF. GIRISH SHAH, the recipient of “Outstanding Achievement in Carcinoid/ Neuroendocrine Tumor Research” in 2006 from the Carcinoid Cancer Foundation, Inc. of USA, is a Professor at the Faculty of Medicine at Laval University in Quebec City. He has been chief of the Laboratory for Skin Cancer Research at the CHU de Quebec (CHUL) Hospital Research Centre of Laval University since 1997. Prof. Shah’s research is focused on carcinoid neuroendocrine tumors and solar ultraviolet radiation-induced skin cancers with specific emphasis on DNA damage, DNA repair and cell death processes, all of which can influence either the development of these cancers or their resistance to therapy. Dr. Shah has authored 55 peer-reviewed articles, which have been cited more than 2,387 times in literature. In addition, he has authored 4 book chapters and 119 presentations at the meetings. Dr. Shah’s team, in collaboration with two carcinoid clinicians in Canada and USA, had earlier reported that nearly ¼ of the carcinoid neuroendocrine tumor patients suffer from subclinical niacin (vitamin B3) deficiency, an incidence that is much higher than pellagra, the clinical niacin deficiency syndrome reported in these patients. His recent work has identified how this biochemical anomaly can be exploited to improve efficiency of chemotherapy of carcinoid NET cancers.

Mandate of SMAB

The SMAB will provide advice on the following:

  • NET-related medical and scientific activities; their relevance and the quality of the science performed and used;

  • Emerging trends in medical and scientific issues pertaining to NETs: the challenges and opportunities in national and global contexts;

  • Knowledge translation and science communication activities;

  • Scientific and Clinical partnerships and linkages; and

  • The science underpinning of specific issues brought before the Board